Optimizing The Management of Type 2 Diabetes Mellitus: Integrating Injectable Anti-diabetes Therapies into Clinical Care

Primary care, endocrinology physicians, physician assistants, nurse practitioner, nurses, other healthcare providers in the management of T2DM

Activity Information

Credits: 1.5 AMA PRA Category 1 Credit(s)
Launch Date: February 11, 2020
Expiration Date: February 11, 2021

COURSE FACULTY

Richard S. Beaser, MD (Course Director)
Senior Staff Physician
Medical Director, Continuing Medical Education
Senior Strategic Advisor, Education Programs
Joslin Diabetes Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Bruce W. Bode, MD, FACE
Clinical Associate Professor of Medicine
Emory University School of Medicine
President and CEO
Atlanta Diabetes Associates
Atlanta, Georgia

Mark W. Stolar, MD
Associate Professor of Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Alissa R. Segal, PharmD, RPh, CDCES, CDTC, FCCP
Professor of Pharmacy Practice
MCPHS University
Clinical Pharmacist, Joslin Diabetes Center
Boston, Massachusetts

LEARNING OBJECTIVES

  1. DESCRIBE the pathophysiology and progression of T2DM as it relates to the eventual need for injectable therapies to manage blood glucose.     
  2. IDENTIFY provider and patient-derived barriers that contribute to clinical inertia regarding the initiation and intensification of injectable therapy in T2DM.
  3. COMPARE the efficacy, safety, and clinical indications of basal insulin, injected and evolving oral GLP1-RAs, and GLP1-RA/insulin FRCs+ as part of T2DM treatment.     
  4. RECOGNIZE clinical scenarios in which progression to an injectable anti-diabetes therapy may be appropriate.
  5. INCORPORATE shared decision-making strategies to facilitate the appropriate utilization of injectable therapies as part of overall T2DM management.

COURSE INFORMATION

Sponsored by

This activity is supported by an educational grant from Novo Nordisk Inc.

GOAL
The goals of this activity are to provide guidance about the clinical use of newer injectable therapies manage patients with T2DM and to offer an opportunity for clinicians to improve their skills in patient evaluation and therapeutic implementation of treatment programs, leveraging multidisciplinary treatment support, utilizing these newer pharmacotherapeutic options.
 
TARGET AUDIENCE
Primary care and endocrinology physicians, physician assistants, nurse practitioner, nurses, and other healthcare providers who participate in the management of patients with T2DM. No prerequisites required.
 
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Joslin Diabetes Center and ASiM CE LLC. Joslin Diabetes Center is accredited by the ACCME to provide continuing medical education for physicians.
 
CREDIT DESIGNATION STATEMENT
Joslin Diabetes Center designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
PARTICIPATING FACULTY
Richard S. Beaser, MD (Course Director)
Senior Staff Physician
Medical Director, Continuing Medical Education
Senior Strategic Advisor, Education Programs
Joslin Diabetes Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
Alissa R. Segal, PharmD, RPh, CDCES, CDTC, FCCP
Professor of Pharmacy Practice
MCPHS University
Clinical Pharmacist, Joslin Diabetes Center
Boston, Massachusetts
 
Bruce W. Bode, MD, FACE
Clinical Associate Professor of Medicine
Emory University School of Medicine
Diabetes Specialist
Atlanta Diabetes Association
Atlanta, Georgia
 
Mark W. Stolar, MD
Associate Professor of Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois
 
FINANCIAL DISCLOSURES
Disclosures of Conflicts of Interest
As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning and/or CME advisory committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning and CME advisory committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services, with the exception of nonprofit or government organizations and non-healthcare-related companies, which are exempt.
 
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.
 
If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of Joslin Diabetes Center.
 
The planners and faculty have reported the following financial relationships with commercial interests. Via Joslin internal review, any relationship deemed relevant to the content of this activity has been identified and resolved through Joslin’s internal processes.
 
The faculty and planning committee members for this program have disclosed the following:
 
Faculty

    Richard S. Beaser, MD, Senior Staff Physician and Medical Director of CME, Joslin Diabetes Center, has no relevant financial relationships with regard to this activity.
    Bruce W. Bode, MD, FACE, Clinical Associate Professor of Medicine, Emory University School of Medicine, has no relevant financial relationships with regard to this activity.
    Alissa R. Segal, PharmD, RPh, CDCES, CDTC, FCCP, Professor of Pharmacy Practice, MCPHS University Clinical Pharmacist, has no relevant financial relationships with regard to this activity.
    Mark W. Stolar, MD, Associate Professor of Clinical Medicine, Feinberg School of Medicine, Northwestern University, has no relevant financial relationships with regard to this activity.

 
Joslin CME Advisory Committee

    Jessica Marshall, PhD, Executive Medical Director, ASiM, CE LLC, has no relevant financial relationships with regard to this activity.
    Wendy Gloffke, PhD, Medical Writer, Medical Writing & Communications, has no relevant financial relationships with regard to this activity.
    Lisa Mangione, Senior Medical Editor, ASiM CE LLC, has no relevant financial relationships with regard to this activity.
    Joslin CME Advisory Committee
    Jerry Cavallerano, OD, Optometrist, Beetham Eye Institute, Joslin Diabetes Center, has no relevant financial relationships.
    Nuha El Sayed, MD, Staff Physician and Medical Director, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.
    Erin Kelly, M.Ed., RN, BSN, CDE, Adult Diabetes Educator, Joslin Diabetes Center, holds stock in Tandem Diabetes Care.
    Lyle Mitzner, MD, Staff Physician, Joslin Diabetes Center, is a consultant for Conversa Health.
    Alissa R. Segal, PharmD, RPh, CDCES, CDTC, FCCP , Clinical Pharmacist, Joslin Diabetes Center, has no relevant financial relationships with regard to this activity.
    Robert C. Stanton, MD, Chief of Nephrology, Joslin Diabetes Center, has no relevant financial relationships
    Elena Toschi, MD, Staff Physician, Joslin Diabetes Center, has no relevant financial relationships.

 
METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.
 
CONTACT INFORMATION
Please send content inquiries to: [email protected].
 
FEE INFORMATION
There is no fee for this educational activity.

COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.        

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above